Switching of Sildenafil to Riociguat in CTEPH Patients

Summary

This study was designed to investigate the safety and efficacy of replacing phosphodiesterase 5 inhibitors (PDE5i) with riociguat in patients with Chronic thromboembolic pulmonary hypertension (CTEPH) who have undergone pulmonary angioplasty (BPA) and remains symptomatic despite treatments with PDE5i.

Timeline

Start

2024-07-25

Primary completion

2026-07-22

Completion

2027-01-22

Publications

• Kam THH, Kam KKH, Wong MKL, Yan BPY, Tan G. Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study. BMC Pulm Med. 2026 Jan 3;26(1):42. doi: 10.1186/s12890-025-04069-y.

Drugs

Indications